Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): Phase I/II trial results.

被引：0
|
作者：
Leonard, JP
Coleman, M
Schuster, MW
Chadburn, A
Ely, S
Yagan, N
Sharkey, RM
Hansen, HJ
Goldenberg, DM
机构：
[1] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Div Hematol Oncol, Ithaca, NY 14853 USA
[2] Cornell Univ, Weill Med Coll, Dept Pathol, Ithaca, NY 14853 USA
[3] Cornell Univ, Weill Med Coll, Dept Radiol, Ithaca, NY 14853 USA
[4] New York Presbyterian Hosp, New York, NY USA
[5] Garden State Canc Ctr, Belleville, NJ USA
[6] Immunomed Inc, Morris Plains, NJ USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
404
引用
收藏
页码：92A / 93A
页数：2
相关论文
共 50 条
  • [1] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    BLOOD, 2002, 100 (11) : 358A - 358A
  • [2] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Ely, S
    Furman, RR
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Cesano, A
    Goldenberg, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3051 - 3059
  • [3] Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Furman, R
    Schuster, MW
    Feldman, EJ
    Ashe, M
    Schuster, SJ
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Fields, SZ
    Cesano, A
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (16) : 5327 - 5334
  • [4] Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab (LymphoCide™ anti-CD22 monoclonal antibody) in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Hajjar, G
    Burton, JD
    Sharkey, RM
    Schuster, SL
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, E
    Leonard, JP
    Coleman, M
    Goldenberg, DM
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
  • [5] Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkin's lymphoma (NHL) patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab.
    Hajjar, G
    Sharkey, RM
    Burton, J
    Schuster, S
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, EA
    Leonard, J
    Coleman, M
    Plutchock, J
    Brenner, AI
    Goldenberg, DM
    BLOOD, 2001, 98 (11) : 611A - 611A
  • [6] Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
    Strauss, Sandra J.
    Morschhauser, Frank
    Rech, Juergen
    Repp, Roland
    Solal-Celigny, Philippe
    Zinzani, Pier L.
    Engert, Andreas
    Coiffier, Bernard
    Hoelzer, Dieter F.
    Wegener, William A.
    Teoh, Nick K. W.
    Goldenberg, David M.
    Lister, T. Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3880 - 3886
  • [7] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Shi, V
    Hayes, M
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878
  • [8] Fractionated-dose radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody (epratuzumab).: Interim results.
    Chatal, JF
    Harousseau, JL
    Truemper, LH
    Meller, J
    Pfreundschuh, M
    Kirsch, CM
    Naumann, R
    Kropp, J
    Wegener, WA
    Ding, C
    Horak, ID
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 408A - 408A
  • [9] Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of dota-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
    Chatal, JF
    Harousseau, JL
    Trümper, LH
    Meller, J
    Pfreundschuh, M
    Kirsch, CM
    Naumann, R
    Kropp, J
    Lateiner, JE
    Wegener, WA
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 525 - 526
  • [10] Final results of a Phase I/II trial of fractionated radioimmunotherapy (RAIT) with anti-CD22 90Y-epratuzumab tetraxetan in relapsed/refractory non-Hodgkin lymphoma (NHL)
    Goldenberg, D. M.
    Kraeber-Bodere, F.
    Morschhauser, F.
    Petillon, M.
    Huglo, D.
    Meller, J.
    Kirsch, C.
    Kropp, J.
    Le Gouil, S.
    Le Gouil, S.
    Bodet-Milin, C.
    Teoh, N.
    Chatal, J.
    Wegener, W. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S237 - S237
12345